Search
Research
The STAMP RSV ProgramSTAMP RSV is a multifaceted program of work with the single focus to prepare the community for the uptake of new and emerging RSV immunisation strategies by providing the evidence to inform public health policy.
Research
Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024Respiratory Syncytial Virus (RSV) causes a significant burden of illness for children under 2 years of age. Nirsevimab, a long-acting monoclonal antibody, was registered for RSV prevention in Australia in 2023. In April 2024, Western Australia (WA) launched the country's first state-wide nirsevimab program for all infants and high-risk children entering their second RSV season.
Research
The pathogen specific burden of hospitalisation for enteric and blood stream infection in children and young people in Western AustraliaHannah Tom Moore Snelling OAM BSc (Hons) GradDipClinEpi PhD BMBS DTMH GDipClinEpid PhD FRACP Head, Infectious Diseases Research Head, Infectious
Research
Understanding the true burden of paediatric respiratory syncytial virus (RSV) in order to optimise prevention programsHannah Moore OAM BSc (Hons) GradDipClinEpi PhD Head, Infectious Diseases Research 08 6319 1427 Hannah.moore@thekids.org.au Head, Infectious Diseases
Research
WHO SARI & RSV Surveillance in AustraliaChristopher Blyth MBBS (Hons) DCH FRACP FRCPA PhD Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases; Co-Head, Infectious Diseases
News & Events
Bold bid to end rheumatic heart diseaseSome of the nation’s leading medical researchers will converge on Darwin this week to step out a plan to wipe out rheumatic heart disease.
Research
Infection and VaccinesListed are The Kids Research Institute Australia research teams involved in our Infection and Vaccines Program. This program sits under the Early Environment research theme.
Research
Can linked emergency department data help assess the out-of-hospital burden of acute lower respiratory infectionsThere is a lack of data on the out-of-hospital burden of acute lower respiratory infections (ALRI) in developed countries.
Research
Economic burden of multidrug-resistant tuberculosis on patients and households: a global systematic review and meta-analysisMultidrug-resistant tuberculosis (MDR-TB) is a major health threat worldwide, causing a significant economic burden to patients and their families. Due to the longer duration of treatment and expensive second-line medicine, the economic burden of MDR-TB is assumed to be higher than drug-susceptible TB.
Research
Determinants of drug-resistant tuberculosis in Hunan province, China: a case-control studyDrug-resistant tuberculosis (DR-TB) is a major public health threat in Hunan Province, with an increasing clinical burden in recent years. This study aimed to identify socio-demographic and clinical factors associated with DR-TB in Hunan province, China.